南模生物(688265) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥88,396,140.55, representing a 6.59% increase compared to ¥82,932,302.56 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥966,819.05, significantly improved from a loss of ¥12,897,060.70 in the previous year, marking a 92.50% reduction in losses[4][8]. - The basic and diluted earnings per share were both -¥0.01, an improvement from -¥0.17 in the same period last year[4]. - Operating profit improved to a loss of CNY 2,239,745.43 from a loss of CNY 12,998,602.81 year-over-year[18]. - Other comprehensive income after tax showed a loss of CNY 43,265.75, improving from a loss of CNY 91,122.93 in the previous year[19]. Cash Flow - The net cash flow from operating activities was a negative ¥26,746,493.35, slightly improved from a negative ¥28,394,359.82 in the same period last year[4]. - Cash inflow from operating activities totaled $68,065,103.00, slightly up from $67,757,018.71 in the previous period[22]. - Total cash outflow from operating activities was $94,811,596.35, compared to $96,151,378.53 in the prior period, showing a decrease in cash outflows[22]. - The net increase in cash and cash equivalents was -$119,506,029.02, compared to a positive increase of $10,740,267.10 in the prior period, indicating a cash depletion[23]. - The ending balance of cash and cash equivalents was $76,708,816.58, down from $108,343,188.50 at the end of the previous period[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,911,115,609.92, a decrease of 0.95% from ¥1,929,356,534.07 at the end of the previous year[5]. - Total liabilities decreased to CNY 227,976,260.32 from CNY 246,356,013.57, a reduction of 7.4%[14]. - Total current assets slightly decreased to ¥1,145,527,515.74 from ¥1,148,284,749.04, a reduction of about 0.2%[12]. - Total non-current assets decreased to ¥765,588,094.18 from ¥781,071,785.03, a reduction of approximately 1.98%[13]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,252[10]. - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, accounting for 35.62% of total shares[10]. Research and Development - Research and development expenses totaled ¥19,755,542.27, accounting for 22.35% of operating revenue, a decrease of 0.96 percentage points from 23.31% in the previous year[5]. - The company reported a decrease in research and development expenses to CNY 19,755,542.27 from CNY 19,334,427.95, indicating a focus on cost management[18]. - The company has no significant new product or technology developments reported in the conference call[12]. Investment Activities - Total cash inflow from investment activities was $691,876,563.18, significantly higher than $296,496,310.15 in the prior period[22]. - The net cash flow from investment activities was -$88,994,587.15, contrasting with a positive $60,121,373.98 in the previous period, reflecting increased investment outflows[22]. - The company made significant investments totaling $777,000,000.00, compared to $230,000,000.00 in the previous period, indicating aggressive expansion strategies[22]. Cost Management - The company plans to continue enhancing cost control through measures such as optimizing production processes and improving delivery timeliness[8]. - Total operating costs decreased to CNY 94,524,575.57 from CNY 99,746,760.11, representing a reduction of 5.4%[18].